AT7519 is a pyrazole-based multi-cyclin dependent kinase inhibitor with IC50 activity against CDK2, CDK5, and CDK9, of 47, 13, and
In a panel of 26 human tumor cell lines, AT7519 showed potent antiproliferative activity at 40-940 nM. 24h treatment of HCT116 cells showed phosphorylation inhibition of CDK1 substrate PP1a (T320) and CDK2 substrates Rb (T821) and NPM (T199). (2)
Technical information:
Chemical Formula: | C16H17Cl2N5O2 | |
CAS #: | 902135-91-5 | |
Molecular Weight: | 382.24 | |
Purity: | > 98% | |
Appearance: | Light Yellow | |
Chemical Name: | 4-(2,6-dichlorobenzamido)-N-(piperidin-4-yl)-1H-pyrazole-3-carboxamide | |
Solubility: | Up to 25 mM in DMSO | |
Synonyms: | AT7519, AT 7519, AT-7519 |
Shipping Condition: The product is shipped in a glass vial at ambient temperature.
Storage condition: For longer shelf life, store solid powder at 4oC desiccated, or store DMSO solution at -20oC.
Reference:
1. | Santo et al., AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3b activation and RNA polymerase II inhibition. Oncogene, 2010, 29, 2325-2336. Pubmed ID: 20101221 |
2. | Squires et al., Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines. 2009, 8, 324-332. Pubmed ID: 19174555 |
Other Information:
Product Specification (pdf)
MSDS (pdf)
Certificate of Analysis is available upon request.